Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3651
Citizens Community Bancorp
CZWI
$206M
| $661K | ﹤0.01% |
37,077
+1,323
| +4% | +$22.2K |
2024 Q3
5 quarters
|
|
|
FBRX
3652
DELISTED
Forte Biosciences
FBRX
| $658K | ﹤0.01% |
24,111
+23,291
| +2,840% | +$408K |
2025 Q3
1 quarter
|
|
3653
BCB Bancorp
BCBP
$261M
| $656K | ﹤0.01% |
81,340
+1,565
| +2% | +$12.6K |
2022 Q2
14 quarters
|
|
3654
Kopin
KOPN
$913M
| $656K | ﹤0.01% |
280,287
+52,496
| +23% | +$152K |
2024 Q4
4 quarters
|
|
3655
Definitive Healthcare
DH
$99.6M
| $655K | ﹤0.01% |
228,349
+177,938
| +353% | +$493K |
2022 Q1
15 quarters
|
|
|
NMAX
3656
Newsmax Inc
NMAX
$1.23B
| $655K | ﹤0.01% |
84,775
+69,266
| +447% | +$665K |
2025 Q2
2 quarters
|
|
3657
United States Natural Gas Fund
UNG
$530M
| $653K | ﹤0.01% |
53,271
-6,948
| -12% | -$93.5K |
2023 Q1
11 quarters
|
|
3658
Nektar Therapeutics
NKTR
$1.49B
| $653K | ﹤0.01% |
15,444
-1,235
| -7% | -$69.1K |
2013 Q2
50 quarters
|
|
|
ABX
3659
Abacus Global Management
ABX
$809M
| $652K | ﹤0.01% |
76,315
+5,951
| +8% | +$39.2K |
2025 Q1
3 quarters
|
|
|
GRSD
3660
Grandstand Ltd
GRSD
$53.8M
| $652K | ﹤0.01% |
119,396
+28,323
| +31% | +$180K |
2022 Q2
14 quarters
|
|
3661
Jakks Pacific
JAKK
$311M
| $651K | ﹤0.01% |
38,571
+447
| +1% | +$7.74K |
2022 Q1
15 quarters
|
|
3662
ClearPoint Neuro
CLPT
$332M
| $647K | ﹤0.01% |
47,313
+9,053
| +24% | +$168K |
2022 Q3
13 quarters
|
|
3663
Northeast Community Bancorp
NECB
$367M
| $647K | ﹤0.01% |
28,601
+3,100
| +12% | +$65.5K |
2022 Q3
13 quarters
|
|
3664
First United
FUNC
$282M
| $647K | ﹤0.01% |
17,269
+6,516
| +61% | +$242K |
2024 Q3
5 quarters
|
|
3665
Thryv Holdings
THRY
$67.5M
| $645K | ﹤0.01% |
106,674
+49,335
| +86% | +$391K |
2022 Q1
15 quarters
|
|
3666
GlobalFoundries
GFS
$28B
| $645K | ﹤0.01% |
18,459
-538,652
| -97% | -$19.2M |
2022 Q1
15 quarters
|
|
3667
Mesa Laboratories
MLAB
$742M
| $643K | ﹤0.01% |
8,186
+523
| +7% | +$39.8K |
2016 Q3
37 quarters
|
|
3668
Consensus Cloud Solutions
CCSI
$648M
| $640K | ﹤0.01% |
29,349
+2,027
| +7% | +$49.9K |
2022 Q1
15 quarters
|
|
3669
Procore
PCOR
$7.74B
| $639K | ﹤0.01% |
8,786
-7,530
| -46% | -$557K |
2022 Q1
15 quarters
|
|
3670
Voyager Therapeutics
VYGR
$151M
| $637K | ﹤0.01% |
162,112
+4,003
| +3% | +$17.7K |
2022 Q3
13 quarters
|
|
3671
Blue Owl Capital
OBDC
$5.08B
| $637K | ﹤0.01% |
51,210
-93,148
| -65% | -$1.18M |
2023 Q1
11 quarters
|
|
3672
Vanguard Information Technology ETF
VGT
$157B
| $636K | ﹤0.01% |
6,752
-567,288
| -99% | -$53.9M |
2016 Q2
38 quarters
|
|
3673
Kodak
KODK
$960M
| $635K | ﹤0.01% |
75,025
-15,187
| -17% | -$114K |
2020 Q2
22 quarters
|
|
3674
Greenlight Captial
GLRE
$481M
| $634K | ﹤0.01% |
43,458
+5,486
| +14% | +$72.1K |
2013 Q4
48 quarters
|
|
3675
Frontier Group Holdings
ULCC
$1.43B
| $632K | ﹤0.01% |
134,284
-17,936
| -12% | -$79.5K |
2021 Q2
18 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.